Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.
Kawamoto Y, Yuki S, Sawada K, Nakamura M, Muto O, Sogabe S, Shindo Y, Ishiguro A, Sato A, Tsuji Y, Dazai M, Okuda H, Meguro T, Harada K, Sekiguchi M, Okada K, Ito YM, Sakata Y, Sakamoto N, Komatsu Y.
Kawamoto Y, et al. Among authors: yuki s.
Oncologist. 2022 Aug 5;27(8):e642-e649. doi: 10.1093/oncolo/oyac086.
Oncologist. 2022.
PMID: 35579511
Free PMC article.
Clinical Trial.